Navigation Links
Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
Date:4/2/2009

CHARLOTTESVILLE, Virginia, April 2 /PRNewswire/ -- Biovista Inc. today announced that BVA-101, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-101, an existing drug that Biovista repositioned in MS and is aimed at neuroprotection, was shown to have both efficacy in reducing symptoms and no toxic effects in this well established model of MS.

"We are excited about these early results that confirm the predictive capability of our repositioning platform technology and encourage us to further develop this compound in a disease area where there is a significant need for new therapies" said Aris Persidis, Ph.D., President of Biovista. "What is also encouraging is that we reached this stage just 4 months after deciding to work in MS. At the present time we are exploring all options available to us, including the further co-development with a pharmaceutical company and the licensing of the IP to a generics company" Dr. Persidis added.

About Biovista's BVA-101 trial in the MS EAE-MOG model

MS is a chronic inflammatory disease of the CNS with unknown etiology. It is the most frequent non-traumatic disabling neurologic disease among young adults, with 12,000 new diagnoses per year in the US alone, and over 2.5 million patients worldwide. In the animal proof of concept trial, BVA-101 was compared to dexamethasone, a potent anti-inflammatory and immunosuppressive drug that is efficient in accelerating the recovery from MS relapses but too toxic for chronic use. BVA-101 induced a statistically significant reduction of EAE severity, the magnitude of which was statistically similar to that caused by dexamethasone.

About Biovista's repositioning pipeline and technology platform

Biovista applies high-throughput discovery efforts to finding solutions for commerci
'/>"/>

SOURCE Biovista Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... UAE (PRWEB) May 21, 2013 ... consultancy specializing in “game-changing” life science and health related ... Dalia Dergham to its International Project Team. Dergham's expertise ... even greater multi-cultural depth to Grace Century as it ... the globe. , Ms. Dergham holds both an under ...
(Date:5/20/2013)... 20, 2013  (PSHR) Pacific Shore Holdings, Inc. ... across a broad range of product categories lines, ... relations firm, BlueWater Advisory Group, to provide strategic ... process, and to direct the company,s outreach and ... Matthew Mills , Pacific Shore ...
(Date:5/20/2013)... , Md. and BALTIMORE , ... (BHI), a regional private-public partnership focusing on ... early-stage funding in Central Maryland ... Ph.D., M.B.A., as the first Entrepreneur-in-Residence (EIR) for ... National Heart, Lung and Blood Institute ...
(Date:5/20/2013)... Interventional cardiologist Tony Farah, MD, and ... Cardiovascular Institute have helped pioneer many breakthroughs ... over the past three decades, from new disease-fighting ... coronary artery stent implantation. , Today, AGH officials announced ... role in the study of a novel, first-of-its kind ...
Breaking Biology Technology:Dalia Dergham Joins Grace Century FZ LLC International Project Team 2Pacific Shore Holdings Retains Investor Relations Firm 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4
... Corporation (Nasdaq: ROCM ) will announce quarterly results ... Company will then,hold a quarterly conference call to discuss ... central daylight time (5:00 p.m. eastern time)., This ... accessed at,Rochester Medical,s website at http://www.rocm.com . To ...
... American Oriental,Bioengineering, Inc. (NYSE: AOB ) today ... results on Monday, August 11, 2008, after the,market closes., ... 5:00 pm ET on August 11,2008 to discuss its ... by dialing 1-800-599-9816 or 1-617-847-8705 for,international callers, access code: ...
... Radiofrequency ... Surgical Technologies -, PALO ALTO, Calif., July 24 ... new tissue dissection system,based on a proprietary technology, today announced that ... to market its,PEAK(R) Surgery System for use in general surgery. The ...
Cached Biology Technology:Rochester Medical Announces Third Quarter 2008 Earnings Conference Call July 31, 2008 2PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in General Surgery 2PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in General Surgery 3PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in General Surgery 4
(Date:5/20/2013)... Foundation (NSF) planning grant will help establish the Center ... of the University of Illinois at Urbana-Champaign and Worcester ... be devoted to research in drying moist, porous materials ... paper products; chemical products; textiles; and biopharmaceuticals," said Hao ... and human nutrition and the Illinois site director. , ...
(Date:5/19/2013)... novel study reports that white men and women of ... (hallux valgus) and lesser toe deformities, including hammer or ... to estimate the heritability of foot disorders in humansappear ... published by Wiley on behalf of the American College ... as many as 60% of older adults have foot ...
(Date:5/18/2013)... (May 18, 2013) Research presented today at Digestive ... research, with findings about the impact of coffee on ... , While coffee consumption recently has been associated with ... even a few more cups of java each month ... liver disease. Researchers at the Mayo Clinic, Rochester, MN, ...
Breaking Biology News(10 mins):NSF approves planning grant for Center for Advanced Research in Drying 2Blame your parents for bunion woes 2Coffee consumption associated with reduced risk of autoimmune liver disease 2
... goes the cynical saying with television and newspaper editors. In other ... the big story on the front page. So one might ... and unhappy types of words like "war," " funeral," "cancer," ... "hero." Or take Twitter. A popular image of what people ...
... BOSTON, January 12, 2012: A research collaboration between ... Harvard University and Children,s Hospital Boston has developed ... selectively deliver drugs to the cells of the ... testing and development before being ready for clinical ...
... Illinois researchers have shown that by tuning the ... nanoantennas, these nano-scale structures allow for dexterous optical ... "Nanoantennas are extremely popular right now because ... in small areas," explained Kimani Toussaint, Jr., an ...
Cached Biology News:We may be less happy, but our language isn't 2We may be less happy, but our language isn't 3New 'smart' nanotherapeutics can deliver drugs directly to the pancreas 2Optical nanoantennas enable efficient multipurpose particle manipulation 2
... Kit, 50 purifications. Allows rapid purification ... removal of unincorporated CyDye label and ... yields of labeled cDNA probe. ... labeled by either direct incorporation or ...
... reagents for the isolation of genomic DNA. ... the isolation of genomic DNA from blood. ... the isolation of genomic DNA from plants. ... be used for restriction endonuclease digestion Southern ...
Detects activated caspases in living cells. Simple/sensitive/straight-forward procedure takes only 30 minutes. Results can be analyzed by flow cytometry/fluorescence microscopy/fluorescence plate rea...
Apoptosis Detection Systems and Reagents...
Biology Products: